May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
Contralateral IOP Effect of Travoprost and Bimatoprost
Author Affiliations & Notes
  • A.M. Golden
    Loyola University Stritch School of Medicine, Chicago, IL
  • M. Shah
    Ophthalmology, Loyola University Health System, Chicago, IL
  • G. Emerick
    Ophthalmology, Loyola University Health System, Chicago, IL
  • Footnotes
    Commercial Relationships  A.M. Golden, None; M. Shah, None; G. Emerick, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 3767. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A.M. Golden, M. Shah, G. Emerick; Contralateral IOP Effect of Travoprost and Bimatoprost . Invest. Ophthalmol. Vis. Sci. 2005;46(13):3767.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: This study was conducted to evaluate the effects of monocular administration of travoprost and bimatoprost on the intraocular pressure (IOP) of the contralateral eye in glaucoma patients, and to compare the relative contralateral efficacy of monocular administration of these two medications. Methods: A retrospective review of patient charts was conducted at Hines Veterans Administration Hospital. The Hines VA pharmacy database was searched for all patients who were prescribed travoprost and bimatoprost for 2 years after the respective drug’s introduction to the VA formulary. Data was collected on only patients who fit all inclusion criteria and underwent a monocular trial of travoprost (n=22) or bimatoprost (n=17). Inclusion criteria included at least a 20% reduction in IOP in treatment eye (classified as a drug responder), an original difference in IOP between eyes of no greater than 4 mmHg, and no prior treatment with prostaglandin analogues. Baseline and follow–up IOP was recorded at 4–6 weeks for both treatment and control eyes. Results: Treatment eye IOP for the travoprost group decreased by a mean of 6.95 mmHg, a 33.3% reduction (p=. 000). Control eye IOP for the travoprost group decreased by a mean of 1.50 mmHg, a 7.1% reduction (p=. 037). Treatment eye IOP for the bimatoprost group decreased by a mean of 6.71 mmHg, a 35.3% reduction (p=. 000). Control eye IOP for the bimatoprost group decreased by 2.03 mmHg, an 11.3% reduction (p=. 012). Comparison of mean decrease in contralateral pressure in mmHg between the two groups did not show a statistically significant difference (p=.60). Conclusions: Both bimatoprost and travoprost applied unilaterally cause a statistically significant decrease in IOP of the contralateral eye. There was no statistically significant difference between the effectiveness of bimatoprost and travoprost on the contralateral eye. The positive contralateral effect of both bimatoprost and travoprost found in this study should be verified by a prospective study.

Keywords: intraocular pressure • pharmacology 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×